| Filed | Form | Description | |
|---|---|---|---|
| 5/9/24 | DEFA14A | DEFA14A | → |
| 4/30/24 | DEFA14A | DEFA14A | → |
| 4/1/24 | DEFR14A | DEFR14A | → |
| 3/27/24 | DEFA14A | DEFA14A | → |
| 3/22/24 | DEFA14A | DEFA14A | → |
| 3/21/24 | DEF 14A | DEF 14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 3/7/24 | SC 13G/A | SC 13G/A | → |
| 2/14/24 | SC 13G/A | AMENDMENT NO. 4 TO THE SCHEDULE 13G | → |
| 1/31/24 | SC 13G | SC 13G | → |
| 1/25/24 | SC 13D/A | SC 13D/A | → |
| 12/28/23 | 4 | 4 | → |
| 12/13/23 | SC 13D/A | SC 13D/A | → |
| ↓ | |||
Merrimack Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, United States.